Nov. 6, 2023, 7:30 a.m. | Business Wire

AI – AI-TechPark ai-techpark.com

Tumor uninformed treatment response monitoring assay for research use only Tempus, a leader in artificial intelligence and precision medicine, today announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients...


The post Tempus announced New ctDNA Assay, xF Monitor first appeared on AI-TechPark.

ai artificial artificial intelligence dna intelligence leader medicine monitoring patients precision precision medicine research treatment

Software Engineer for AI Training Data (School Specific)

@ G2i Inc | Remote

Software Engineer for AI Training Data (Python)

@ G2i Inc | Remote

Software Engineer for AI Training Data (Tier 2)

@ G2i Inc | Remote

Data Engineer

@ Lemon.io | Remote: Europe, LATAM, Canada, UK, Asia, Oceania

Artificial Intelligence – Bioinformatic Expert

@ University of Texas Medical Branch | Galveston, TX

Lead Developer (AI)

@ Cere Network | San Francisco, US